Key Takeaways
- Topline stalled by weather, not demand: Net sales grew just +0.9% as unseasonal rains and a cyclone crushed Glucon-D’s peak summer season; the rest of the portfolio grew closer to double digits.
- One-off costs cratered EBITDA: EBITDA fell 21.3% YoY, driven by a ₹14.2 crore worker settlement, legal charges, inventory write-offs, plus higher alternative fuel and statutory wage costs.
- Complan’s pricing reset is working: A revised pack-price architecture, responding to aggressive competitor LUPs, drove a 12% jump in household usage at the MAT level, though value share is still catching up.
- Margin recovery is a multi-year project: Management targets a climb back to 17–18% EBITDA margin from the current ~15%, but only over the next two to three years, as investment continues.
- What to watch next quarter: Whether Glucon-D recovers lost summer volume in a seasonally weaker period, the pace of milk price pass-through, and any early signal from the new Sugar Free campaign.
The Glucon-D Shock
- Weather, not brand health: Unseasonal rains across key states and Cyclone Biparjoy hit during Glucon-D’s short April–May peak cycle, compressing the entire season. The glucose powder category itself degrew 3% at the MAT level, so the brand’s internal growth rates still outperformed the category.
- Regional split tells the story: East and South regions, which saw less rain disruption, performed well; North and West bore the brunt of the weather impact.
- Nycil was insulated: Because humidity as well as heat drives prickly heat demand, Nycil’s season was less disrupted and it delivered strong growth with a 117 bps market share gain.
Tarun Arora: "we do not have a doubt in terms of the fact that we can deliver a consistent over three years to four years, double-digit growth."
Complan & the HFD Price War
- The reset: Complan revised its pack-price architecture after a competitor introduced aggressive low-unit packs and price reductions roughly 1.5–2 years ago. That competitor action, per management, “destroyed the whole pricing architecture” of the category.
- Volume recovery is visible: Household usage grew 12% at the MAT level, and volume market share has been recovering for several quarters. Value share recovery will lag until the pricing environment normalizes.
- Milk inflation looms: The company plans to take price increases in coming quarters to address milk inflation, even as the base dairy portfolio (butter, ghee) continues to perform well.
- Nutralite’s mixed bag: The core dairy portfolio delivered robust growth, but the chocolate spread launch fell much below expectations; mayonnaise has achieved some mass distribution with room to expand.
Dr. Sharvil Patel: "I think also this whole -- the lower price point architecture that got introduced, I think, has a detrimental effect on the overall category. So maybe short term, it looked very good, but it has destroyed the whole pricing architecture."
Sugar Free: A Category at a Crossroads
- Growth has slowed to mid-single digits, driven by three headwinds: a perception that the product is only for diabetics, price challenges, and the emerging aspartame controversy. Management said it is too early to see any demand impact from the WHO aspartame assessment.
- Stevia is the bright spot: Stevia-based products are growing at high double digits, and the company plans to launch more products under Sugar Free leveraging both Sucralose and Stevia to overcome aspartame perception challenges.
- New campaign deployed: A fresh communication, “Katrina’s Fitness wali chai,” launched in Q2, aiming to reposition the brand around a healthier lifestyle rather than a medical need.
- Investment priority: Sugar Free and Everyuth will receive focused marketing investment over the next six months; other brands will see more measured spend.
Margin Structure & Cost Headwinds
- The EBITDA drop was structural as well as one-off: Beyond the ₹14.2 crore one-time charge (worker settlement, legal, inventory write-offs), manufacturing costs rose from higher alternative fuel prices and a statutory wage rate increase. Savings from the Sitarganj plant cessation partially offset HR costs but could not absorb the full wage and fuel spike.
- Gross margin improved in non-milk portfolio: Non-milk based products saw gross margin expansion in excess of 100 bps year-on-year, but this was overwhelmed by the top-line miss and fixed-cost deleverage.
- Next two quarters stay soft: Management flagged that margins will remain structurally lower in the near term because fixed costs stay similar while gross margins drop from mix, with the focus on delivering better growth over the prior year.
- The recovery path: From the current ~15% EBITDA margin, the target is 17–18% over two to three years, with investment continuing alongside the climb. Working capital is expected to improve by 10–13 days versus last year.
Tarun Arora: "we believe that in the next two years to three years, we should be looking at recovering back to 17% to 18% because we dropped down to 15%... we have to invest back also."
Competitive Dynamics & Disclosure Boundaries
- Prickly heat market share dispute: An analyst noted a competitor claiming the number-one position in prickly heat powder on a combined-brand basis. Management pushed back sharply, arguing brands cannot be arithmetically combined because each has its own capability and customer set, and stated they have seen no change in their own position.
- Household gain vs. share loss not fully reconciled: When asked how Complan’s 12% household usage gain coexists with a 31 bps market share decline, management began explaining about inflation and higher-priced categories before the audio dropped. On reconnection, they cited new consumer gains and hyperinflation reducing assumptions, but the reconciliation remained incomplete.
- Everyuth and Nycil breakups withheld: Management declined to provide individual revenue breakouts for the two brands, offering only the combined level.
Dr. Sharvil Patel: "I don't think you can combine two brands and say, become number one like that because each brand has its own capability and own customer set. So you don't replace just because -- you don't combine brands like that."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Still has a shot at double-digit for the full year, with three quarters remaining including a large Q4 | FY24 (hopeful, not assured) |
| EBITDA margin recovery | Climb back to 17–18% from current ~15% | Next 2–3 years |
| Working capital improvement | 10–13 days improvement vs. last year | FY24 |
| Volume-led growth | Consistent double-digit volume growth, accelerated by innovations | Over 3–4 years |
| Milk price pass-through | Appropriate price increases to address milk inflation | Coming quarters |
| Marketing investment focus | Sugar Free and Everyuth receive focused spend; others measured | Next six months |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Net sales | ₹699.2 cr, +0.9% YoY |
| Total income from operations | ₹702.1 cr, +0.8% YoY |
| EBITDA | ₹116.5 cr, -21.3% YoY |
| EBITDA margin | 16.7% (per an analyst's math) |
| Reported net profit | ₹110.4 cr, -19.4% YoY |
| Adjusted net profit (excl. exceptional items) | ₹124.6 cr, -10.9% YoY |
| One-time expenditure | ₹14.2 cr, towards worker settlement, legal charges and inventory write-offs |
| Other expenses growth | +13.6% YoY, driven by alternative fuel costs and statutory wage increases |
| Overall volume growth | -5.2% YoY |
| Volume growth excl. Glucon-D | +4.5% YoY |
| Non-milk portfolio gross margin improvement | >100 bps YoY |
| EBITDA margin target (medium-term) | 17% to 18% over next 2-3 years, recovering from 15% |
| Glucon-D market share | 59.9%, -57 bps YoY (MAT June '23) |
| Complan market share | 4.5% (MAT June '23) |
| Complan household usage growth | +12% at MAT level |
| Sugar Free market share | 96.2% |
| Everyuth scrub market share | 42.4%, +42 bps YoY (MAT June '23) |
| Everyuth peel-off market share | 78.7%, +19 bps YoY (MAT June '23) |
| Nycil market share | 35.5%, +117 bps YoY (MAT June '23) |
| Working capital improvement target | 10 to 13 days improvement vs last year |
| Tax benefit availability | Until March '25, normal tax rate applicable |